Recombinant protein derived from the N-terminus of human CYLD protein
Conjugate
Unconjugated
Form
Frozen
Concentration
0.5 mg/ml
Purification
Protein A
Storage buffer
PBS, pH 7.4
Preservative
0.1% sodium azide
Storage Conditions
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Tested Applications
Dilution *
Immunocytochemistry (ICC)
1 µg/ml
Immunofluorescence (IF)
1 µg/ml
Immunohistochemistry (Paraffin) (IHC (P))
1:10-1:50
Western Blot (WB)
Assay Dependent
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Background/Target Information
CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
原厂资料：
注意事项：
For Research Use Only. Not for use in diagnostic procedures.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
